They demonstrated that earlier expression of RUNX1-RUNX1T1, as early as postnatal day 3, resulted in a higher AML penetrance and lower incidence of non-AML disease compared to mice where RUNX1-RUNX1T1 expression was induced at 8-16 weeks of age. Here, RUNX1 is linked to acute myeloid leukemia.